• Males or females between age 60 and 85 years, inclusive, at time of consent.

• Have a dedicated partner/caregiver informant who is in the company of the participant at least 12 hours a week, who can accompany them to scheduled visits, and who is able to provide accurate reporting upon the behavioral, cognitive and functional abilities of the participant.

• Be physically able to participate with adequate visual acuity and auditory discrimination.

• Be willing / able to provide written informed consent or assent.

• Must reside within a proximity of the study site that will not preclude their regularly-scheduled participation in the trial, as well as a catchment area for local lab blood draws (i.e. central contracted laboratory).

• Meet criteria for probable AD dementia according to the National Institute of Aging - Alzheimer's Association (NIA-AA) 2018 core research criteria, and have the following at screening:

‣ A diagnosis of mild AD or moderate AD, or

⁃ A provisional research diagnosis consistent with probable mild AD or moderate AD, and

⁃ MoCA score of 4-24 inclusive.

• Have positive biomarker for brain amyloid pathology as shown by:

‣ Positive plasma assay for Aβ(42)/ Aβ(40) ratio AND

⁃ Either postivie CSF assay for AD assessment or positive amyloid PET, per PI read.

• If receiving anti-dementia treatment (i.e. AChEI), be on stable treatment for at least 2 months (i.e., cholinesterase inhibitor and/or Memantine) before initial screening visit.

• Be stable on all other medications for at least 30 days prior to initial screening visit.